AtriCure Net Worth
AtriCure Net Worth Breakdown | ATRC |
AtriCure Net Worth Analysis
AtriCure's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including AtriCure's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of AtriCure's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform AtriCure's net worth analysis. One common approach is to calculate AtriCure's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares AtriCure's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing AtriCure's net worth. This approach calculates the present value of AtriCure's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of AtriCure's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate AtriCure's net worth. This involves comparing AtriCure's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into AtriCure's net worth relative to its peers.
Enterprise Value |
|
To determine if AtriCure is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding AtriCure's net worth research are outlined below:
| The company reported the previous year's revenue of 465.31 M. Net Loss for the year was (44.7 M) with profit before overhead, payroll, taxes, and interest of 373.52 M. | |
| Over 97.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Atricure Director Makes a Significant Stock Sale - TipRanks |
AtriCure Quarterly Good Will |
|
AtriCure uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in AtriCure. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to AtriCure's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
AtriCure Target Price Consensus
AtriCure target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. AtriCure's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 9 | Strong Buy |
Most AtriCure analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand AtriCure stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of AtriCure, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAtriCure Target Price Projection
AtriCure's current and average target prices are 35.39 and 49.89, respectively. The current price of AtriCure is the price at which AtriCure is currently trading. On the other hand, AtriCure's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On AtriCure Target Price
Know AtriCure's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as AtriCure is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading AtriCure backward and forwards among themselves. AtriCure's institutional investor refers to the entity that pools money to purchase AtriCure's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Marshall Wace Asset Management Ltd | 2025-03-31 | 994.1 K | Fmr Inc | 2025-03-31 | 993 K | Gw&k Investment Management, Llc | 2025-03-31 | 981.5 K | Nuveen, Llc | 2025-03-31 | 950.6 K | Goldman Sachs Group Inc | 2025-03-31 | 862.7 K | Bnp Paribas Investment Partners Sa | 2025-03-31 | 747.8 K | Dimensional Fund Advisors, Inc. | 2025-03-31 | 711 K | Wellington Management Company Llp | 2025-03-31 | 702.1 K | Two Sigma Investments Llc | 2025-03-31 | 667.9 K | Vanguard Group Inc | 2025-03-31 | 4.7 M | Blackrock Inc | 2025-03-31 | 4.2 M |
Follow AtriCure's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.75 B.Market Cap |
|
Project AtriCure's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.14) | (0.15) | |
| Return On Capital Employed | (0.07) | (0.08) | |
| Return On Assets | (0.07) | (0.08) | |
| Return On Equity | (0.10) | (0.10) |
When accessing AtriCure's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures AtriCure's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of AtriCure's profitability and make more informed investment decisions.
Please note, the presentation of AtriCure's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, AtriCure's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of AtriCure's management manipulating its earnings.
Evaluate AtriCure's management efficiency
AtriCure has return on total asset (ROA) of (0.0353) % which means that it has lost $0.0353 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0785) %, meaning that it created substantial loss on money invested by shareholders. AtriCure's management efficiency ratios could be used to measure how well AtriCure manages its routine affairs as well as how well it operates its assets and liabilities. As of August 11, 2025, Return On Tangible Assets is expected to decline to -0.15. In addition to that, Return On Capital Employed is expected to decline to -0.08. At present, AtriCure's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 358.6 M, whereas Other Assets are forecasted to decline to 0.86.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 9.82 | 10.31 | |
| Tangible Book Value Per Share | 3.61 | 3.79 | |
| Enterprise Value Over EBITDA | (74.95) | (78.69) | |
| Price Book Value Ratio | 3.11 | 3.71 | |
| Enterprise Value Multiple | (74.95) | (78.69) | |
| Price Fair Value | 3.11 | 3.71 | |
| Enterprise Value | 73.6 M | 54.9 M |
The strategic initiatives led by AtriCure's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 3.4292 | Revenue | Quarterly Revenue Growth 0.171 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AtriCure insiders, such as employees or executives, is commonly permitted as long as it does not rely on AtriCure's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases AtriCure insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
AtriCure Corporate Filings
F4 | 8th of August 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 30th of July 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 29th of July 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 29th of May 2025 Other Reports | ViewVerify |
AtriCure Earnings Estimation Breakdown
The calculation of AtriCure's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of AtriCure is estimated to be -0.0908 with the future projection ranging from a low of -0.1 to a high of -0.08. Please be aware that this consensus of annual earnings estimates for AtriCure is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.1 Lowest | Expected EPS | -0.08 Highest |
AtriCure Earnings Projection Consensus
Suppose the current estimates of AtriCure's value are higher than the current market price of the AtriCure stock. In this case, investors may conclude that AtriCure is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and AtriCure's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 9 | 51.64% | 0.0 | -0.0908 | -0.77 |
AtriCure Earnings per Share Projection vs Actual
Actual Earning per Share of AtriCure refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering AtriCure predict the company's earnings will be in the future. The higher the earnings per share of AtriCure, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.AtriCure Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as AtriCure, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of AtriCure should always be considered in relation to other companies to make a more educated investment decision.AtriCure Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact AtriCure's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-07-28 | 2025-06-30 | -0.167 | -0.02 | 0.147 | 88 | ||
2025-04-29 | 2025-03-31 | -0.2234 | -0.14 | 0.0834 | 37 | ||
2025-02-13 | 2024-12-31 | -0.1488 | -0.08 | 0.0688 | 46 | ||
2024-10-29 | 2024-09-30 | -0.19 | -0.17 | 0.02 | 10 | ||
2024-07-30 | 2024-06-30 | -0.17 | -0.17 | 0.0 | 0 | ||
2024-05-01 | 2024-03-31 | -0.23 | -0.28 | -0.05 | 21 | ||
2024-02-15 | 2023-12-31 | -0.23 | -0.21 | 0.02 | 8 | ||
2023-11-01 | 2023-09-30 | -0.31 | -0.2 | 0.11 | 35 | ||
2023-07-25 | 2023-06-30 | -0.3 | -0.11 | 0.19 | 63 | ||
2023-05-02 | 2023-03-31 | -0.34 | -0.23 | 0.11 | 32 | ||
2023-02-21 | 2022-12-31 | -0.18 | -0.09 | 0.09 | 50 | ||
2022-11-01 | 2022-09-30 | -0.25 | -0.27 | -0.02 | 8 | ||
2022-08-02 | 2022-06-30 | -0.29 | -0.32 | -0.03 | 10 | ||
2022-05-03 | 2022-03-31 | -0.32 | -0.33 | -0.01 | 3 | ||
2022-02-15 | 2021-12-31 | -0.29 | -0.3 | -0.01 | 3 | ||
2021-11-03 | 2021-09-30 | -0.32 | 2.11 | 2.43 | 759 | ||
2021-08-04 | 2021-06-30 | -0.33 | -0.36 | -0.03 | 9 | ||
2021-04-27 | 2021-03-31 | -0.37 | -0.38 | -0.01 | 2 | ||
2021-02-23 | 2020-12-31 | -0.28 | -0.28 | 0.0 | 0 | ||
2020-11-05 | 2020-09-30 | -0.34 | -0.11 | 0.23 | 67 | ||
2020-07-28 | 2020-06-30 | -0.57 | -0.2 | 0.37 | 64 | ||
2020-04-29 | 2020-03-31 | -0.41 | -0.42 | -0.01 | 2 | ||
2020-02-18 | 2019-12-31 | -0.41 | -0.42 | -0.01 | 2 | ||
2019-10-30 | 2019-09-30 | -0.27 | -0.25 | 0.02 | 7 | ||
2019-07-30 | 2019-06-30 | -0.18 | -0.11 | 0.07 | 38 | ||
2019-04-25 | 2019-03-31 | -0.24 | -0.15 | 0.09 | 37 | ||
2019-02-28 | 2018-12-31 | -0.17 | -0.09 | 0.08 | 47 | ||
2018-11-01 | 2018-09-30 | -0.22 | -0.22 | 0.0 | 0 | ||
2018-08-01 | 2018-06-30 | -0.23 | -0.19 | 0.04 | 17 | ||
2018-04-26 | 2018-03-31 | -0.27 | -0.31 | -0.04 | 14 | ||
2018-02-26 | 2017-12-31 | -0.21 | -0.2 | 0.01 | 4 | ||
2017-11-01 | 2017-09-30 | -0.24 | -0.22 | 0.02 | 8 | ||
2017-07-27 | 2017-06-30 | -0.26 | -0.21 | 0.05 | 19 | ||
2017-05-04 | 2017-03-31 | -0.35 | -0.32 | 0.03 | 8 | ||
2017-02-28 | 2016-12-31 | -0.31 | -0.27 | 0.04 | 12 | ||
2016-10-27 | 2016-09-30 | -0.28 | -0.21 | 0.07 | 25 | ||
2016-08-04 | 2016-06-30 | -0.3 | -0.26 | 0.04 | 13 | ||
2016-04-28 | 2016-03-31 | -0.32 | -0.31 | 0.01 | 3 | ||
2016-02-23 | 2015-12-31 | -0.34 | -0.36 | -0.02 | 5 | ||
2015-10-27 | 2015-09-30 | -0.22 | -0.22 | 0.0 | 0 | ||
2015-07-28 | 2015-06-30 | -0.21 | -0.18 | 0.03 | 14 | ||
2015-04-29 | 2015-03-31 | -0.21 | -0.19 | 0.02 | 9 | ||
2015-02-23 | 2014-12-31 | -0.2 | -0.2 | 0.0 | 0 | ||
2014-10-30 | 2014-09-30 | -0.17 | -0.02 | 0.15 | 88 | ||
2014-07-24 | 2014-06-30 | -0.19 | -0.2 | -0.01 | 5 | ||
2014-04-24 | 2014-03-31 | -0.22 | -0.21 | 0.01 | 4 | ||
2014-02-27 | 2013-12-31 | -0.14 | -0.24 | -0.1 | 71 | ||
2013-10-29 | 2013-09-30 | -0.15 | -0.13 | 0.02 | 13 | ||
2013-08-01 | 2013-06-30 | -0.1 | -0.09 | 0.01 | 10 | ||
2013-05-02 | 2013-03-31 | -0.11 | -0.1 | 0.01 | 9 | ||
2013-02-28 | 2012-12-31 | -0.1 | -0.12 | -0.02 | 20 | ||
2012-11-01 | 2012-09-30 | -0.12 | -0.16 | -0.04 | 33 | ||
2012-08-02 | 2012-06-30 | -0.07 | -0.08 | -0.01 | 14 | ||
2012-05-02 | 2012-03-31 | -0.14 | -0.1 | 0.04 | 28 | ||
2012-02-27 | 2011-12-31 | -0.07 | -0.13 | -0.06 | 85 | ||
2011-11-01 | 2011-09-30 | -0.08 | -0.07 | 0.01 | 12 | ||
2011-08-02 | 2011-06-30 | -0.05 | -0.06 | -0.01 | 20 | ||
2011-05-04 | 2011-03-31 | -0.07 | -0.08 | -0.01 | 14 | ||
2011-02-16 | 2010-12-31 | -0.07 | 8.0E-4 | 0.0708 | 101 | ||
2010-11-02 | 2010-09-30 | -0.1 | -0.07 | 0.03 | 30 | ||
2010-08-04 | 2010-06-30 | -0.12 | -0.05 | 0.07 | 58 | ||
2010-05-10 | 2010-03-31 | -0.1 | -0.13 | -0.03 | 30 | ||
2010-02-18 | 2009-12-31 | -0.09 | -0.15 | -0.06 | 66 | ||
2009-11-04 | 2009-09-30 | -0.1 | -0.06 | 0.04 | 40 | ||
2009-08-04 | 2009-06-30 | -0.08 | -0.1 | -0.02 | 25 | ||
2009-05-05 | 2009-03-31 | -0.19 | -0.08 | 0.11 | 57 | ||
2009-02-19 | 2008-12-31 | -0.18 | -0.22 | -0.04 | 22 | ||
2008-11-04 | 2008-09-30 | -0.15 | -0.12 | 0.03 | 20 | ||
2008-08-05 | 2008-06-30 | -0.17 | -0.11 | 0.06 | 35 | ||
2008-05-06 | 2008-03-31 | -0.22 | -0.25 | -0.03 | 13 | ||
2008-02-14 | 2007-12-31 | -0.2 | -0.11 | 0.09 | 45 | ||
2007-11-06 | 2007-09-30 | -0.26 | -0.18 | 0.08 | 30 | ||
2007-08-09 | 2007-06-30 | -0.27 | -0.22 | 0.05 | 18 | ||
2007-05-10 | 2007-03-31 | -0.29 | -0.35 | -0.06 | 20 | ||
2007-02-15 | 2006-12-31 | -0.43 | -0.35 | 0.08 | 18 | ||
2006-11-08 | 2006-09-30 | -0.4 | -0.26 | 0.14 | 35 | ||
2006-08-08 | 2006-06-30 | -0.34 | -0.26 | 0.08 | 23 | ||
2006-05-04 | 2006-03-31 | -0.36 | -0.24 | 0.12 | 33 | ||
2006-02-16 | 2005-12-31 | -0.31 | -0.33 | -0.02 | 6 | ||
2005-11-03 | 2005-09-30 | -0.33 | -0.5 | -0.17 | 51 |
AtriCure Corporate Management
| Deborah Yount | Chief Officer | Profile | |
| Tonya SPHR | VP HR | Profile | |
| Vinayak Doraiswamy | Chief Officer | Profile | |
| JD CCEP | Chief Officer | Profile | |
| Salvatore JD | Chief Officer | Profile | |
| CCEP CCEP | Chief Officer | Profile |
Already Invested in AtriCure?
The danger of trading AtriCure is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of AtriCure is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than AtriCure. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile AtriCure is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether AtriCure offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AtriCure's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atricure Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atricure Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AtriCure. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade AtriCure Stock refer to our How to Trade AtriCure Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AtriCure. If investors know AtriCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AtriCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.77) | Revenue Per Share | Quarterly Revenue Growth 0.171 | Return On Assets | Return On Equity |
The market value of AtriCure is measured differently than its book value, which is the value of AtriCure that is recorded on the company's balance sheet. Investors also form their own opinion of AtriCure's value that differs from its market value or its book value, called intrinsic value, which is AtriCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AtriCure's market value can be influenced by many factors that don't directly affect AtriCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AtriCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if AtriCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AtriCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.